Cary Street Partners Investment Advisory’s Sarepta Therapeutics SRPT Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-254	Closed	-$30.8K	–	1659
2023 Q3	$30.8K	Buy	254 +154	+154%	+$17.4K	﹤0.01%	988
2023 Q2	$11.5K	Hold	100	–	–	﹤0.01%	1203
2023 Q1	$13.8K	Hold	100	–	–	﹤0.01%	1067
2022 Q4	$13K	Buy	+100	New	+$11.6K	﹤0.01%	1079
2020 Q4	–	Sell	-150	Closed	-$21K	–	801
2020 Q3	$21K	Buy	+150	New	+$22.8K	﹤0.01%	643

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cary Street Partners Investment Advisory's SRPT Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 254 shares — an estimated $30.8K sold.

Cary Street Partners Investment Advisory first reported a position in SRPT in Q3 2020 and held it in 5 quarters. The position peaked at $30.8K in Q3 2023. 396 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

Cary Street Partners Investment Advisory reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 254 Sarepta Therapeutics shares in Q4 2023, an estimated $30.8K.
Cary Street Partners Investment Advisory first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 5 quarters.
Cary Street Partners Investment Advisory's Sarepta Therapeutics position peaked at $30.8K in Q3 2023.
396 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.